ANI Pharmaceuticals has acquired a pipeline of seven development stage generic products from Coeptis Pharmaceuticals for $2.3 million dollars and up to $12 million in additional development and commercial milestones. As part of the agreement, ANI will pay a portion of gross profit generated from one of the injectable products to the commercial manufacturing partner. Included in the purchase price, ANI is also acquiring raw materials (API), manufacturing and packaging components, and reference dr...